|
Name |
Endocrocin
|
Molecular Formula | C16H10O7 | |
IUPAC Name* |
1,6,8-trihydroxy-3-methyl-9,10-dioxoanthracene-2-carboxylic acid
|
|
SMILES |
CC1=CC2=C(C(=C1C(=O)O)O)C(=O)C3=C(C2=O)C=C(C=C3O)O
|
|
InChI |
InChI=1S/C16H10O7/c1-5-2-7-12(14(20)10(5)16(22)23)15(21)11-8(13(7)19)3-6(17)4-9(11)18/h2-4,17-18,20H,1H3,(H,22,23)
|
|
InChIKey |
UZOHDKGTYVTYDZ-UHFFFAOYSA-N
|
|
Synonyms |
Endocrocin; 481-70-9; 1,6,8-trihydroxy-3-methyl-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid; N1OEA1S070; 1,6,8-trihydroxy-3-methyl-9,10-dioxoanthracene-2-carboxylic acid; 9,10-Dihydro-1,6,8-trihydroxy-3-methyl-9,10-dioxo-2-anthracenecarboxylic acid; UNII-N1OEA1S070; CHEMBL5078404; SCHEMBL23199115; ACon1_001814; CHEBI:64450; DTXSID90197418; NCGC00180111-01; Q27133290; 2-ANTHRACENECARBOXYLIC ACID, 9,10-DIHYDRO-1,6,8-TRIHYDROXY-3-METHYL-9,10-DIOXO-; NCGC00180111-02!1,6,8-trihydroxy-3-methyl-9,10-dioxoanthracene-2-carboxylic acid
|
|
CAS | 481-70-9 | |
PubChem CID | 160483 | |
ChEMBL ID | CHEMBL5078404 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 314.25 | ALogp: | 2.2 |
HBD: | 4 | HBA: | 7 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 132.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 23 | QED Weighted: | 0.541 |
Caco-2 Permeability: | -5.878 | MDCK Permeability: | 0.00000593 |
Pgp-inhibitor: | 0.009 | Pgp-substrate: | 0.008 |
Human Intestinal Absorption (HIA): | 0.128 | 20% Bioavailability (F20%): | 0.405 |
30% Bioavailability (F30%): | 0.999 |
Blood-Brain-Barrier Penetration (BBB): | 0.019 | Plasma Protein Binding (PPB): | 99.28% |
Volume Distribution (VD): | 0.451 | Fu: | 2.60% |
CYP1A2-inhibitor: | 0.286 | CYP1A2-substrate: | 0.077 |
CYP2C19-inhibitor: | 0.028 | CYP2C19-substrate: | 0.041 |
CYP2C9-inhibitor: | 0.459 | CYP2C9-substrate: | 0.055 |
CYP2D6-inhibitor: | 0.043 | CYP2D6-substrate: | 0.107 |
CYP3A4-inhibitor: | 0.175 | CYP3A4-substrate: | 0.057 |
Clearance (CL): | 2.148 | Half-life (T1/2): | 0.647 |
hERG Blockers: | 0.022 | Human Hepatotoxicity (H-HT): | 0.291 |
Drug-inuced Liver Injury (DILI): | 0.99 | AMES Toxicity: | 0.689 |
Rat Oral Acute Toxicity: | 0.028 | Maximum Recommended Daily Dose: | 0.152 |
Skin Sensitization: | 0.285 | Carcinogencity: | 0.187 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.441 |
Respiratory Toxicity: | 0.142 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001929 | 0.794 | D0N1FS | 0.340 | ||||
ENC005279 | 0.778 | D0K8KX | 0.330 | ||||
ENC000571 | 0.654 | D07MGA | 0.312 | ||||
ENC000335 | 0.648 | D04AIT | 0.308 | ||||
ENC002067 | 0.646 | D01XDL | 0.272 | ||||
ENC000094 | 0.643 | D0H1AR | 0.272 | ||||
ENC000966 | 0.622 | D01XWG | 0.271 | ||||
ENC002296 | 0.620 | D07JHH | 0.267 | ||||
ENC005280 | 0.617 | D0C9XJ | 0.265 | ||||
ENC001058 | 0.595 | D07VLY | 0.265 |